- Home
- About ASF
- What is Autism?
- How Common is Autism?
- Signs and Symptoms of Autism
- Autism Diagnosis
- Following a Diagnosis
- Treatment Options
- Beware of Non-Evidence-Based Treatments
- Statement on Use of Medical Marijuana for People with Autism
- Statement on Use of Applied Behavior Analysis (ABA) for Autism
- Autism and Vaccines
- Autism Science
- Quick Facts About Autism
- What We Fund
- Get Involved
- Resources
- COVID-19 Resources
- Day of Learning
- Contact Us
Podcast: Can IGF-1 treat autism symptoms? A clinical trial aims to find out
Published September 10, 2018
Researchers at Mount Sinai led by Alex Kolevzon are running a clinical trial of the compound insulin-like growth factor 1 (IGF-1) for children with idiopathic autism. Dr. Kolevzon’s team previously demonstrated the safety and feasibility of IGF-1 in treating Phelan-McDermid syndrome, a single-gene form of autism. Particularly, the IGF-1 treatment improved symptoms of social impairment and repetitive behaviors, which are core symptoms of autism. Expanding their investigation into idiopathic autism, the researchers are working hard to make sure families can comfortably and knowledgeably participate in the clinical trial. For this week’s podcast, Mahir Rahman spoke with Dr. Kolevzon about the study and where it hopes to go. Interested in joining the study? Go here to learn more.
Filed under: Alex Kolevzon, ASD, Autism, clinical trial, drug, featured, IGF-1, insulin-like growth factor 1, intervention, medication, Mount Sinai, Phelan-McDermid Syndrome, PMS, restricted and repetitive behavior, social impairment, Treatment